We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

106 hedge funds and large institutions have $568M invested in Nurix Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 46 increasing their positions, 30 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 30

10.07% more ownership

Funds ownership: 90.03% → 100.1% (+10%)

0% more capital invested

Capital invested by funds: $566M → $568M (+$2.5M)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

9% less funds holding

Funds holding: 117 → 106 (-11)

41% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 22

Holders
106
Holders Change
-11
Holders Change %
-9.4%
% of All Funds
1.79%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
13
Increased
46
Reduced
30
Closed
22
Calls
$2.14M
Puts
–
Net Calls
+$2.14M
Net Calls Change
+$111K

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$27.6M
2
BBA
Baker Bros. Advisors
New York
+$16.2M
3
BlackRock
BlackRock
New York
+$9.42M
4
WA
Wasatch Advisors
Utah
+$8.12M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.58M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$8.95M
2
EAM
Eventide Asset Management
Massachusetts
-$8.12M
3
FCMI
Foresite Capital Management IV
California
-$4.01M
4
EC
EcoR1 Capital
California
-$3.56M
5
WP
Woodline Partners
California
-$3.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
101
Group One Trading
Illinois
$1K – – –
US Bancorp
102
US Bancorp
Minnesota
$1K – – –
Bank of Montreal
103
Bank of Montreal
Ontario, Canada
$289 +$273K +24,104 New
EC
104
EcoR1 Capital
California
– -$3.56M -254,473 Closed
WP
105
Woodline Partners
California
– -$3.07M -219,281 Closed
Citadel Advisors
106
Citadel Advisors
Florida
– -$2.4M -211,783 Closed
ROTUOC
107
Regents of the University of California
California
– -$2.86M -204,123 Closed
Alyeska Investment Group
108
Alyeska Investment Group
Illinois
– -$1.69M -120,750 Closed
Two Sigma Investments
109
Two Sigma Investments
New York
– -$1.28M -91,335 Closed
Point72 Asset Management
110
Point72 Asset Management
Connecticut
– -$979K -69,850 Closed
Qube Research & Technologies (QRT)
111
Qube Research & Technologies (QRT)
United Kingdom
– -$462K -33,003 Closed
LCM
112
Laurion Capital Management
New York
– -$399K -28,470 Closed
PHP
113
Parkman Healthcare Partners
Connecticut
– -$289K -20,663 Closed
Squarepoint
114
Squarepoint
New York
– -$287K -20,516 Closed
GCP
115
GSA Capital Partners
United Kingdom
– -$224K -15,963 Closed
ECM
116
ExodusPoint Capital Management
New York
– -$211K -15,034 Closed
GCM
117
Graham Capital Management
Connecticut
– -$173K -12,350 Closed
Two Sigma Advisers
118
Two Sigma Advisers
New York
– -$171K -12,200 Closed
HSBC Holdings
119
HSBC Holdings
United Kingdom
– -$165K -11,615 Closed
ProShare Advisors
120
ProShare Advisors
Maryland
– -$148K -10,489 Closed
PHK
121
Point72 Hong Kong
Hong Kong
– -$16K -1,109 Closed
ECM
122
EMC Capital Management
Texas
– -$3K -288 Closed
TWA
123
TCI Wealth Advisors
Arizona
– -$4K -269 Closed
S
124
SignatureFD
Georgia
– -$1K -48 Closed
Simplex Trading
125
Simplex Trading
Illinois
– -$147 -13 -65%
2 3 4
5
6

NRIX Hedge Fund Activity: Q2 2022 in Review

106 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q2 2022, worth a combined $568M — up 0.44% from $566M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of NRIX and 13 opened new positions — a net loss of 9 holders — while 30 trimmed existing stakes and 46 added.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $27.6M. The largest seller was Wellington Management Group, cutting an estimated $8.95M.

  • 106 institutional investors held Nurix Therapeutics (NRIX) as of Q2 2022, down from 117 in Q1 2022.
  • Funds reported $568M of Nurix Therapeutics stock for Q2 2022, up 0.44% quarter-over-quarter.
  • 13 funds opened new Nurix Therapeutics positions in Q2 2022 and 22 closed out, a net change of -9 holders.
  • The largest Nurix Therapeutics buyer in Q2 2022 was Deep Track Capital, an estimated $27.6M added.
  • The largest Nurix Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $8.95M sold.

Based on aggregated 13F filings for Q2 2022.